Arjo AB (publ) (FRA:A39)
Germany · Delayed Price · Currency is EUR 3.022
-0.038 (-1.24%)
At close: Aug 1, 2025, 10:00 PM CET
Inozyme Pharma Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 430 | 498 | 480 | 449 | 742 | 526 | Upgrade |
Depreciation & Amortization | 1,066 | 1,040 | 1,027 | 951 | 914 | 905 | Upgrade |
Other Amortization | 38 | 38 | 32 | 34 | 42 | 65 | Upgrade |
Loss (Gain) From Sale of Assets | -32 | -32 | -28 | -10 | 3 | 8 | Upgrade |
Asset Writedown & Restructuring Costs | 153 | 111 | 73 | 41 | - | 70 | Upgrade |
Loss (Gain) on Equity Investments | 9 | 9 | 11 | 10 | 9 | - | Upgrade |
Other Operating Activities | -137 | -75 | -59 | -138 | 100 | 71 | Upgrade |
Change in Accounts Receivable | -136 | -98 | 130 | -76 | 135 | 214 | Upgrade |
Change in Inventory | -77 | - | 192 | -164 | -232 | -30 | Upgrade |
Change in Other Net Operating Assets | -8 | 25 | 203 | -270 | 21 | 438 | Upgrade |
Operating Cash Flow | 1,306 | 1,516 | 2,061 | 827 | 1,734 | 2,267 | Upgrade |
Operating Cash Flow Growth | -31.23% | -26.44% | 149.21% | -52.31% | -23.51% | 81.07% | Upgrade |
Capital Expenditures | -522 | -393 | -403 | -557 | -760 | -807 | Upgrade |
Sale of Property, Plant & Equipment | 97 | 97 | 75 | 20 | 85 | 23 | Upgrade |
Cash Acquisitions | -57 | -55 | - | - | -19 | -49 | Upgrade |
Sale (Purchase) of Intangibles | -285 | -285 | -276 | -254 | - | - | Upgrade |
Investment in Securities | - | - | -34 | -21 | - | -139 | Upgrade |
Other Investing Activities | - | 1 | 1 | -1 | -1 | - | Upgrade |
Investing Cash Flow | -767 | -635 | -637 | -813 | -695 | -972 | Upgrade |
Long-Term Debt Issued | - | 26,835 | 23,730 | 24,328 | 9,942 | 8,574 | Upgrade |
Long-Term Debt Repaid | - | -27,601 | -25,030 | -24,124 | -11,138 | -9,118 | Upgrade |
Net Debt Issued (Repaid) | -232 | -766 | -1,300 | 204 | -1,196 | -544 | Upgrade |
Common Dividends Paid | -259 | -245 | -232 | -313 | -232 | -177 | Upgrade |
Other Financing Activities | 16 | 104 | 105 | 245 | 151 | -242 | Upgrade |
Financing Cash Flow | -475 | -907 | -1,427 | 136 | -1,277 | -963 | Upgrade |
Foreign Exchange Rate Adjustments | -38 | -5 | -22 | 42 | 22 | -22 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | -1 | - | - | - | Upgrade |
Net Cash Flow | 26 | -31 | -26 | 192 | -216 | 310 | Upgrade |
Free Cash Flow | 784 | 1,123 | 1,658 | 270 | 974 | 1,460 | Upgrade |
Free Cash Flow Growth | -49.71% | -32.27% | 514.07% | -72.28% | -33.29% | 195.55% | Upgrade |
Free Cash Flow Margin | 6.96% | 9.95% | 15.10% | 2.71% | 10.74% | 16.08% | Upgrade |
Free Cash Flow Per Share | 2.88 | 4.12 | 6.09 | 0.99 | 3.58 | 5.36 | Upgrade |
Cash Interest Paid | 260 | 260 | 250 | 116 | 89 | 101 | Upgrade |
Cash Income Tax Paid | 198 | 192 | 166 | 233 | 132 | 132 | Upgrade |
Levered Free Cash Flow | 474.63 | 512 | 1,405 | 63.75 | 712.13 | 1,479 | Upgrade |
Unlevered Free Cash Flow | 616.5 | 668.88 | 1,569 | 135.63 | 766.5 | 1,568 | Upgrade |
Change in Net Working Capital | 273 | 368 | -574 | 539 | 142 | -809 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.